0000899243-20-021565.txt : 20200805 0000899243-20-021565.hdr.sgml : 20200805 20200805194528 ACCESSION NUMBER: 0000899243-20-021565 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200803 FILED AS OF DATE: 20200805 DATE AS OF CHANGE: 20200805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Turtle Cameron CENTRAL INDEX KEY: 0001758363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 201079305 MAIL ADDRESS: STREET 1: C/O EIDOS THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-03 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001758363 Turtle Cameron C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO CA 94104 0 1 0 0 Chief Business Officer Common Stock 2020-08-03 4 M 0 5000 13.20 A 80531 D Common Stock 2020-08-03 4 S 0 2800 39.0471 D 77731 D Common Stock 2020-08-03 4 S 0 6700 40.2495 D 71031 D Common Stock 2020-08-03 4 S 0 500 40.8927 D 70531 D Stock Option (Right to Buy) 13.20 2020-08-03 4 M 0 5000 0.00 D 2028-11-05 Common Stock 5000 80000 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2019. Represents the weighted average sale price of the shares sold from $38.63 to $39.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 through 4. Represents the weighted average sale price of the shares sold from $39.72 to $40.66 per share. Represents the weighted average sale price of the shares sold from $40.80 to $41.018 per share. 25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. /s/ Franco Valle, as Attorney-in-Fact 2020-08-05